SEOUL, South Korea--(BUSINESS WIRE)--Qurient Co. Ltd. (KRX: 115180), a clinical-stage biotech company based in Korea, today announced that the first patient has been dosed in the Phase 1/2 dose-escalation and expansion study of Q901 in patients with advanced solid tumors.
The Q901 Phase 1/2 study (NCT05394103) is being conducted at six investigative sites in the U.S., and approximately 70 patients with advanced solid tumors are scheduled to be enrolled. The primary objectives of the Phase 1/2 study are to determine the maximum tolerated dose, safety profile, and anticancer efficacy of Q901.
Kiyean Nam, Ph.D., CEO of Qurient, commented, “The initiation of this study represents a significant milestone for Qurient as it marks the second oncology program to enter into clinical development. We look forward to the eventual completion of this Phase 1/2 study, which will guide the further development of Q901 both as monotherapy and in combination with other standard of care therapies that could benefit from genomic instability triggered by Q901.”
Q901 is a highly selective CDK7 inhibitor that disrupts tumor cells division cycle progression and blocks DNA damage repair, resulting in tumor cell apoptosis. The genomic instability triggered by Q901 not only contributes to cell death but also provokes immune surveillance against tumor cells. Q901 is the company’s second oncology drug candidate being developed to treat patients with advanced solid tumors.
In preclinical studies, Q901 has demonstrated a high level of tumor growth inhibition activity as a monotherapy in a variety of tumor models, including prostate, pancreatic, colorectal, and breast cancers, that do not respond to conventional therapies. Q901 also has substantial activity in other preclinical cancer models where CDK4/6 cell cycle inhibitors have minimal or reduced activity
About Qurient Co. Ltd.
Qurient is a clinical-stage biopharmaceutical company listed on the Korea Exchange (KRX: 115180). The company focuses on the development of novel therapeutics for oncology and inflammatory diseases from discovery to human proof-of-concept through a virtual R&D project management platform. Qurient’s pipeline includes multiple drug candidates in preclinical to Phase 2 clinical development. In September 2022, Qurient announced collaboration agreement with MSD to evaluate Q901 in combination with KEYTRUDA® (pembrolizumab). For more info, please visit www.qurient.com.